Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth
This article was originally published in The Gray Sheet
Executive Summary
“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.
You may also be interested in...
HeartWare Touts Early Success In U.S. Launch Of HVAD
HeartWare sold 134 HVAD ventricular assist systems in the U.S. following FDA approval in November and continues to rapidly add more centers to its customer base.
Pressure Builds In Ventricular Assist Market
With only two companies, Thoratec and HeartWare International, selling LVADs in the US, clinical data along with sales and product pipeline strategies have become paramount for capturing market share – and expanding the market to treat a wide range of class III heart failure patients.
Study In Circulation Questions Cost Effectiveness Of VADs
A recent analysis of the cost effectiveness of ventricular assist devices used as destination therapy for heart failure suggests room for improvement.